Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals
- First Online:
- Cite this article as:
- Krzyzanski, W., Sutjandra, L., Perez-Ruixo, J.J. et al. Pharm Res (2013) 30: 655. doi:10.1007/s11095-012-0894-2
- 556 Views
Romiplostim is a novel thrombopoiesis-stimulating peptibody that targets the thrombopoietin c-Mpl receptor, resulting in increased platelet production. The pharmacodynamic-mediated disposition (PDMDD) and its stimulatory effect on platelet production in Sprague-Dawley rats, rhesus monkeys, and cynomolgus monkeys following IV bolus and SC administration at various dose levels were determined.
The pharmacokinetic (PK) profile was described by a PDMDD model that accounts for romiplostim binding to the c-Mpl receptor. The PD model contained a series of aging compartments for precursor cells in bone marrow and platelets. The stimulatory function was described by an on-and-off function operating on the fractional receptor occupancy (RO). The threshold effect, ROthr, and KD parameters were determinants of drug potency, whereas Smax reflected drug efficacy.
The model implicated that receptor-mediated clearance was negligible. ROthr estimated occupancies were 0.288, 0.385, 0.771 for rats, rhesus, and cynomolgus monkeys, respectively. The analogous estimated values of KD were 4.05, 2320, and 429 ng/mL, implying that romiplostim was much more potent in rats, which was confirmed by a dose-response (ratio of peak platelet count to baseline) relationship.
The model adequately described romiplostim serum concentrations and platelet counts in rats, rhesus monkeys, and cynomolgus monkeys, and quantified linear clearance, PDMDD, and potency of romiplostim.
KEY WORDSc-Mpl receptorpeptibodypharmacodynamics-mediated drug disposition (PDMDD)pharmacokinetic and pharmacodynamic modeling
area under the curve from 0 to infinity
- BaF3-Mpl cells
coefficient of variation
enzyme-linked immunosorbent assay
human immunoglobulin G subtype 1
recombinant human thrombopoietin